Rare immuno-mediated adverse events: literature review
- Авторлар: Degtiareva E.A1, Protsenko S.A1, Imyanitov E.N1
-
Мекемелер:
- N.N. Petrov National Medical Research Center of Oncology
- Шығарылым: Том 27, № 7 (2020)
- Беттер: 8-14
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312711
- DOI: https://doi.org/10.18565/pharmateca.2020.7.8-14
- ID: 312711
Дәйексөз келтіру
Аннотация
Immune checkpoint inhibitors have heralded the advent of a “new era" in cancer treatment, significantly improving long-term survival of patients. While these novel agents are often well tolerated, they are widely known to cause a unique profile of immune-mediated toxicities. Any organ systems can be harmed be immune therapy, but the skin, gastro-intestinal tract, liver, lungs and endocrine system are most commonly affected. In recent years, an increasing number of atypical and sometimes life-threatening side effects have been reported, which requires early recognition and prompt intervention. This article reviews rare immune-related adverse events, their diagnosis and management.
Толық мәтін
Авторлар туралы
E. Degtiareva
N.N. Petrov National Medical Research Center of Oncology
Email: degtyarevaekaterina@mail.ru
Oncologist, Postgraduate student at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation 68, Leningradskaya str., Pesochny settlement, St. Petersburg 197758, Russian Federation
S. Protsenko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
E. Imyanitov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
Әдебиет тізімі
- Schoenfeld S.R., Aronow M.E., Leaf R.K., et al. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist. 2020;25(1):6-14. doi: 10.1634/theoncologist.2019-0083.
- Kim J.M., Materin M.A., Sznol M., et al. Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. Ophthalmology. 2019;126(7):1058-62. doi: 10.1016/j.ophtha.2019.01.031.
- Fang T, Maberley D.A., and Etminanb M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol. 2019;31(3):319-22. doi: 10.1016/j.joco.2019.05.002.
- Michel L, Rassaf T., Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. IJC Heart & Vasculature. 2019;25:100420. Doi: 10.1016/j. ijcha.2019.100420.
- Agrawal N, Khunger A., Vachhani P, et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. Case Rep Oncol. 2019;12:260-76. doi: 10.1159/000498985.
- Johnson D.B., Balko J.M., Compton M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749-55. Doi: 10.1056/ NEJMoa1609214.
- Mahmood S.S., Fradley M.G., Cohen J.V., et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755-64. Doi: 10.1016/j. jacc.2018.02.037.
- Moslehi J.J., Salem J.E., Sosman J.A., et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2019; 391 (10124):933. doi: 10.1016/s0140-6736(18)30533-6.
- Upadhrasta S., Elias H., Patel K., et al. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med. 2019;5(1):6-14. doi: 10.1016/j.cdtm.2019.02.004.
- National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Management of Immunotherapy-Related Toxicities, Version 1.2020 - December 16, 2019. Accessed at https://www.nccn.org/ professionals/physician_gls/pdf/immunotherapy. pdf on Februrary 25, 2020.
- Curigliano G., Lenihan D., Fradley M., et al. Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations. Ann Oncol. 2020;31(2):171-90. Doi: 10.1016/j. annonc.2019.10.023.
- Saade A., Mansuet-Lupo A., Arrondeau J., et al. Pericardial effusion under nivolumab: case-reports and review of the literature. J Immunother Cancer. 2019;7:266. doi: 10.1186/s40425-019-0760-4.
- Khan A., Zhang H., Chen C., et al. Impact of pericardial effusion for patients receiving immune checkpoint inhibitors. J Clin Oncol. 2019;37:e14121-e14121. Doi: 10.1200/ JCO.2019.37.15_suppl.e14121.
- Shaheen S., Mirshahidi H., Nagaraj G., et al. Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. Exp Hematol Oncol 2018;7:11. doi: 10.1186/s40164-018-0104-y.
- Chen D.Y, Huang W.K., Chien-Chia Wu V., et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immunooncology. J Formos Med Assoc. 2019;pii:S0929-6646(19)30408-5. doi: 10.1016/j.jfma.2019.07.025.
- Ederhy S., Cautela J., Ancedy Y, et al. Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging 2018;11(18):1187-90. Doi: 10.1016/j. jcmg.2017.11.036.
- Lyon A.R., Yousaf N., Battisti N.M.L., et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447-e458. doi: 10.1016/S1470-2045(18)30457-1.
- Cautela J., Rouby F., Salem J.E., et al. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can J Cardiol 2020;36(4):476-81. Doi: 10.1016/j. cjca.2019.11.035
- Al-Kindi S.G., Oliveira G.H. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for oncocardiology. Mayo Clin Proc 2016;91(1):81-3. doi: 10.1016/j.mayocp.2015.09.009
- Gelsomino F., Fiorentino M., Zompatori M., et al. Programmeddeath-1inhibitionandatherosclerosis: can nivolumab vanish complicated atheromatous plaques? Ann. Oncol. 2018;29(1):284-86. doi: 10.1093/annonc/mdx718
- Daxini A., Cronin K. and Sreih A.G. Vasculitis associated with immune checkpoint inhibitors - a systematic review. Clin Rheumatol. 2018;37:2579-84. doi: 10.1007/s10067-018- 4177-0
- Jamal S., Hudson M., Fifi-Mah A., et al. Immunerelated Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol. 2020;47:166-75. doi: 10.3899/jrheum.190084
- Reynolds K.L., Guidon A.C. Diagnosis and Management of Immune Checkpoint InhibitorAssociated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. 2019;24(4):435-43. Doi: 10.1634/ theoncologist.2018-0359
- Connolly C., Bambhania K. and Naidoo J. Immune Related Adverse Events: A Case-Based Approach. Front Oncol. 2019;9:530. Doi: 10.3389/ fonc.2019.00530
- Möhn N., Beutel G., Gutzmer R., et al. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook. J Clin Med. 2019;8(11):1777. doi: 10.3390/jcm8111777
- Cuzzubbo S., Javeri F., Tissier M., et al. Neurological adverse events associated with immune checkpoint 20 inhibitors: Review of the literature. Eur J Cancer. 2017;73:1-8. doi: 10.1016/j.ejca.2016.12.001
- Johnson D.B., Manouchehri A., Haugh A.M., et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2020;7(1):134. doi: 10.1186/s40425-019-0617-x
- Safa H., Johnson D.H., Trinh V.A., et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1):319. doi: 10.1186/s40425-019- 0774-y
- Gravbrot N., Scherer K. and Sundararajan S. Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature. Case Rep Oncol Med. 2019;2019:5490707. doi: 10.1155/2019/5490707
- Gaudy-Marqueste C., Monestier S., Franques J., et al. A severe case of ipilimumab-induced GuillainBarre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumabinduced colitis. J Immunother. 2013;36(1):77-8. doi: 10.1097/CJI.0b013e31827807dd
- Bhatia S.,Huber B.R.,Upton M.P.,etal.Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother. 2009;32(2):203-5. doi: 10.1097/CJI.0b013e318193a206
- Brahmer J.R., Lacchetti C., Schneider B.J., et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714-68. Doi: 10.1200/ JCO.2017.77.6385
- Haanen J., Carbonnel F., Robert C., et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-42. doi: 10.1093/annonc/ mdx225